Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group. - Wikidata - wikimedia - TriplyDB

Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group.

Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group.

http://www.wikidata.org/entity/Q33376938

about

A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer.Immunomodulatory Response Triggered by the Alkaloids, 3-Amino-7-Benzylbenzimidazo[3,2-a] Quinolinium Chloride (ABQ-48) and 3-Nitro-7-Benzylbenzimidazo [3,2-a] Quinolinium Chloride (NBQ-48)Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer.Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study.

P2860

Q33651496-E1E6973F-35BA-44B7-9C66-2A146475EF69 Q35743952-E586ADB2-F6CD-4CBC-BBA4-C05B1700B90A Q36584405-384DF396-3DA5-436D-B9EB-703E3471DD8E Q37459590-8EA43A80-72AE-4B6B-B9BE-7B4CE8DA3C98 Q44616736-69817F5A-A52E-4F93-A42F-9CA0BEC2003C

P2860

Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group.

http://www.wikidata.org/entity/Q33376938

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Intensified dose of cyclophosp ...... d study from the GINECO group.

@ast

Intensified dose of cyclophosp ...... d study from the GINECO group.

@en

type

label

Intensified dose of cyclophosp ...... d study from the GINECO group.

@ast

Intensified dose of cyclophosp ...... d study from the GINECO group.

@en

prefLabel

Intensified dose of cyclophosp ...... d study from the GINECO group.

@ast

Intensified dose of cyclophosp ...... d study from the GINECO group.

@en

P1433

Q33376938-CF60D606-832C-4B70-A733-339B0E0E6D61

P1476

Q33376938-2220068B-BBC7-4A53-B288-EBC15B5DB115

P2093

Q33376938-07F9E685-861F-4B5F-90B4-781E1C559A91

Q33376938-11080A45-BD11-49E6-8934-3690782C2176

Q33376938-28B7EC1D-C05F-49C1-A8A9-3C4DB724E5D5

Q33376938-366283F4-B028-43E8-9C83-139B7F8A8757

Q33376938-4EEEC53D-C672-4616-9142-535666691DC3

Q33376938-7C2DAF97-8548-4C13-B195-E8FBE35F5C63

Q33376938-B0DD5356-C4E6-4A44-B7CF-4CF98A56DC51

Q33376938-B12BFCF4-0D42-4CAD-A67E-ED4AA2578EE3

Q33376938-D8E095DA-ED61-44DA-810B-877F9220D82E

Q33376938-E9137496-7D39-4F0E-9A29-575315748A2C

P2860

Q33376938-2874F9BD-B72C-4F59-A26A-BBDC15129509

Q33376938-4D985BC8-F1BA-4448-B00D-BC810996CD78

Q33376938-6C1B3900-6470-43CE-96B2-9E23CB8A5774

Q33376938-6D87524E-57D8-43F9-A860-5AB5C467FA25

Q33376938-767F26E5-2F22-4C86-B4FF-6411862787C6

Q33376938-79E94D8A-8E0B-44A9-BFDB-7BC811C31326

Q33376938-84A68EC1-138B-45CE-AD00-F5FEA708C427

Q33376938-B7C8742D-FB5B-49E5-B750-9149428E4BCA

Q33376938-C9976433-7A23-4DC5-810B-88CE1B5A56A1

Q33376938-CEE538E7-FAE2-4764-9E12-59584A129045

P2888

Q33376938-A795149C-1053-4409-8DDE-919AC6805791

P304

Q33376938-B1E6EAD1-9756-4A6E-B7DD-11796B28A97E

P31

Q33376938-FF655BF8-A0EC-45FB-85E2-E5DA872398B8

P356

Q33376938-CCDDCEAC-C97B-44FD-9CEA-09BC97599CDD

P407

Q33376938-46575631-91FB-4773-8320-DC3D66BE4D69

P433

Q33376938-2FBBB068-EB59-41B3-AC63-17D2CB68E1FD

P478

Q33376938-42800421-6B06-482E-90F1-327ABD79CE11

P50

Q33376938-414F7561-2637-4B9B-A207-334DB71CD6B3

P577

Q33376938-FD166573-BE0C-4474-8B02-501C729ECB45

P5875

Q33376938-04BBE113-DF01-4459-8C3C-10A70ED22795

P6179

Q33376938-C12BCEEF-D63C-4785-9B7E-C53CA0793855

P698

Q33376938-1AF1958E-1B71-4011-BB0C-EFCEA35803AB

P921

Q33376938-85F4796B-5CC3-45BE-9413-07B83D5A521E

P932

Q33376938-EBA050AD-ED8D-4508-8A17-2767673799B1

P356

P1433

British Journal of Cancer

P1476

Intensified dose of cyclophosp ...... d study from the GINECO group.

@en

P2093

B Leduc

http://www.w3.org/2001/XMLSchema#string

C Martin

http://www.w3.org/2001/XMLSchema#string

D Castera

http://www.w3.org/2001/XMLSchema#string

D Lepillé

http://www.w3.org/2001/XMLSchema#string

D Paraiso

http://www.w3.org/2001/XMLSchema#string

E Pujade-Lauraine

http://www.w3.org/2001/XMLSchema#string

F Guichard

http://www.w3.org/2001/XMLSchema#string

H Gautier

http://www.w3.org/2001/XMLSchema#string

H Orfeuvre

http://www.w3.org/2001/XMLSchema#string

J-P Guastalla

http://www.w3.org/2001/XMLSchema#string

P2860

Statistical aspects of the analysis of data from retrospective studies of disease

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.

Chemotherapy of ovarian cancer.

Options for primary chemotherapy of epithelial ovarian cancer: taxanes.

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer.

P2888

P304

1200-1205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604026

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

Isabelle Ray-Coquard

P577

2007-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5920916

http://www.w3.org/2001/XMLSchema#string

P6179

1014639357

http://www.w3.org/2001/XMLSchema#string

P698

17923867

http://www.w3.org/2001/XMLSchema#string

P921

P932

2360456

http://www.w3.org/2001/XMLSchema#string